Dynamic Changes of HER2 Expression in Breast Cancers after Neoadjuvant Chemotherapy with the Inclusion of HER2-low Category

被引：0
|
作者：
Karakas, Cansu [1 ]
Tyburski, Haley [2 ]
Liu, Elena [1 ]
Hicks, David [1 ]
Zhang, Huina [1 ]
机构：
[1] Univ Rochester, Med Ctr, Rochester, NY 14642 USA
[2] Univ Rochester, Rochester, NY USA
来源：
LABORATORY INVESTIGATION | 2023年 / 103卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
163
引用
收藏
页码：S151 / S152
页数：2
相关论文
共 50 条
  • [21] Pathological complete response rate and disease-free survival after neoadjuvant chemotherapy in patients with HER2-low and HER2-0 breast cancers
    de Nonneville, Alexandre
    Houvenaeghel, Gilles
    Cohen, Monique
    Sabiani, Laura
    Bannier, Marie
    Viret, Frederic
    Goncalves, Anthony
    Bertucci, Francois
    CANCER RESEARCH, 2023, 83 (05)
  • [22] Re: Pathologic complete responses, long-term outcomes, and recurrence patterns in HER2-low vs. HER2-zero breast cancer after neoadjuvant chemotherapy Several issues about HER2 expression and neoadjuvant chemotherapy in breast cancer
    Yang, Fan
    Liu, Guanmo
    Mao, Feng
    Zheng, Yong-Chang
    EUROPEAN JOURNAL OF CANCER, 2023, 180 : 184 - 185
  • [23] Evaluation of HER2 scoring algorithms for identification of HER2-low breast cancer
    Costache, S.
    Nagy, A.
    Billingham, K.
    Haynes, H.
    Chefani, A.
    Thomas, T.
    Wedden, S.
    D'Arrigo, C.
    VIRCHOWS ARCHIV, 2020, 477 : S222 - S223
  • [24] The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer
    Wei Wang
    Tingting Zhu
    Hao Chen
    Yongzhong Yao
    Clinical and Translational Oncology, 2023, 25 : 1673 - 1681
  • [25] The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer
    Wang, Wei
    Zhu, Tingting
    Chen, Hao
    Yao, Yongzhong
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2023, 25 (06): : 1673 - 1681
  • [26] Impact of HER2 status (HER2-low versus HER2-0) on complete histologic response after neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC)
    Domergue, C.
    Martin, E.
    Lemarie, C.
    Jezequel, P.
    Frenel, J-S.
    Augereau, P.
    Campone, M.
    Patsouris, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S428 - S429
  • [27] HER2-Low Breast Cancer Can Be Visualized by HER2 PET Reply
    Seban, Romain-David
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (11) : 1841 - 1842
  • [28] Clinicopathological characteristics and value of HER2-low expression evolution in breast cancer receiving neoadjuvant chemotherapy
    Shao, Yingbo
    Guan, Huijuan
    Luo, Zhifen
    Yu, Yang
    He, Yaning
    Chen, Qi
    Liu, Chaojun
    Zhu, Fangyuan
    Liu, Hui
    BREAST, 2024, 73
  • [29] Effect of HER2-low expression on neoadjuvant efficacy in operable breast cancer
    Yi, Xiaoli
    Hu, Shasha
    Ma, Meili
    Huang, Dongshuai
    Zhang, Yan
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (04): : 880 - 890
  • [30] Effect of HER2-low expression on neoadjuvant efficacy in operable breast cancer
    Xiaoli Yi
    Shasha Hu
    Meili Ma
    Dongshuai Huang
    Yan Zhang
    Clinical and Translational Oncology, 2024, 26 : 880 - 890
12345